Envestnet Asset Management
ADMA icon

Envestnet Asset Management’s ADMA Biologics ADMA Stock Holding History

Envestnet Asset Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-122,790
Closed -$1.11M – 4825
2026
Q1 		$1.11M Buy
122,790
+43,611
+55% +$688K ﹤0.01% 3415
2025
Q4 		$1.44M Sell
79,179
-36,080
-31% -$608K ﹤0.01% 3061
2025
Q3 		$1.69M Sell
115,259
-27,970
-20% -$479K ﹤0.01% 2994
2025
Q2 		$2.61M Buy
143,229
+74,543
+109% +$1.52M ﹤0.01% 2645
2025
Q1 		$1.36M Buy
68,686
+8,682
+14% +$150K ﹤0.01% 2984
2024
Q4 		$1.03M Buy
60,004
+24,293
+68% +$457K ﹤0.01% 3155
2024
Q3 		$714K Buy
35,711
+22,595
+172% +$351K ﹤0.01% 3313
2024
Q2 		$147K Buy
13,116
+1,929
+17% +$16.2K ﹤0.01% 4003
2024
Q1 		$73.8K Buy
+11,187
New +$61.1K ﹤0.01% 4085
2023
Q4 		– Sell
-22,245
Closed -$79.6K – 4045
2023
Q3 		$79.6K Buy
22,245
+4,814
+28% +$18.5K ﹤0.01% 3899
2023
Q2 		$64.3K Buy
17,431
+6,989
+67% +$25.9K ﹤0.01% 3860
2023
Q1 		$34.6K Buy
+10,442
New +$36.1K ﹤0.01% 3890

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Envestnet Asset Management's ADMA Position: Q2 2026 in Review

Envestnet Asset Management sold out of ADMA Biologics (ADMA) in Q2 2026, closing a stake of 122,790 shares — an estimated $1.11M sold.

Envestnet Asset Management first reported a position in ADMA in Q1 2023 and held it in 12 quarters. The position peaked at $2.61M in Q2 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Envestnet Asset Management reported no remaining ADMA Biologics position as of Q2 2026 after selling out during the quarter.
  • Envestnet Asset Management sold 122,790 ADMA Biologics shares in Q2 2026, an estimated $1.11M.
  • Envestnet Asset Management first reported a position in ADMA Biologics in Q1 2023 and held it in 12 quarters.
  • Envestnet Asset Management's ADMA Biologics position peaked at $2.61M in Q2 2025.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.